Last reviewed · How we verify
Lac-Hydrin (AMMONIUM LACTATE)
Lac-Hydrin (AMMONIUM LACTATE) is a small molecule alpha-Hydroxy Acid developed by RANBAXY and currently owned by Sun Pharm Inds Inc. It was FDA approved in 1985 for various skin conditions, including atopic dermatitis, contact dermatitis, and dry skin. Lac-Hydrin is available as a generic medication, with multiple manufacturers, and is off-patent. It is used to treat a range of skin issues, including itching and irritation. Key safety considerations include potential skin irritation and allergic reactions.
At a glance
| Generic name | AMMONIUM LACTATE |
|---|---|
| Sponsor | Sun Pharma |
| Drug class | alpha-Hydroxy Acid [EPC] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Ichthyosis vulgaris
- Xerosis
Common side effects
- rash (including erythema and irritation)
- burning/stinging
- itching
- transient burning
- stinging
- dry skin
- rash
Key clinical trials
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Repeated Examinations for Typing Pulmonary Embolism
- Evaluating Prognostic Contribution of Lactate on Recovery of Spontaneous Cardiac Activity After Cardiac Arrest (NA)
- Effect of Liberal and Restrictive IV Fluids on Recovery After Gallbladder Surgery (PHASE1)
- Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy (PHASE2)
- Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lac-Hydrin CI brief — competitive landscape report
- Lac-Hydrin updates RSS · CI watch RSS
- Sun Pharma portfolio CI